PureTech accesses the underlying pathophysiology of disease at multiple dimensions rather than through a single receptor or pathway. Our strong clinical and preclinical pipeline is centered on areas where new approaches are urgently needed and there is a strong scientific evidence of benefit, from new tools to diagnose and treat cognitive disorders, to strategies that bolster the role of the microbiome across multiple disease processes.
“PureTech has the scientific creativity to really go for the big ideas that can be game changers. The team dreams up technologies and then makes them happen”
- Dr. Robert Langer, PureTech Co-Founder & Non-Executive Director